U.S. markets open in 5 hours 28 minutes
  • S&P Futures

    4,325.50
    +7.75 (+0.18%)
     
  • Dow Futures

    34,045.00
    +2.00 (+0.01%)
     
  • Nasdaq Futures

    14,065.25
    +78.50 (+0.56%)
     
  • Russell 2000 Futures

    1,921.10
    -7.20 (-0.37%)
     
  • Crude Oil

    86.92
    +0.31 (+0.36%)
     
  • Gold

    1,794.00
    -1.00 (-0.06%)
     
  • Silver

    22.61
    -0.07 (-0.29%)
     
  • EUR/USD

    1.1141
    -0.0006 (-0.06%)
     
  • 10-Yr Bond

    1.8070
    0.0000 (0.00%)
     
  • Vix

    30.44
    -1.52 (-4.76%)
     
  • GBP/USD

    1.3372
    -0.0009 (-0.07%)
     
  • USD/JPY

    115.5100
    +0.2080 (+0.18%)
     
  • BTC-USD

    36,663.85
    +222.70 (+0.61%)
     
  • CMC Crypto 200

    830.75
    +11.24 (+1.37%)
     
  • FTSE 100

    7,507.39
    -46.92 (-0.62%)
     
  • Nikkei 225

    26,717.34
    +547.04 (+2.09%)
     

What Type Of Shareholders Own The Most Number of Synairgen plc (LON:SNG) Shares?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • BSEAF
  • SYGGF

Every investor in Synairgen plc (LON:SNG) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned.

With a market capitalization of UK£368m, Synairgen is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about Synairgen.

Check out our latest analysis for Synairgen

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Synairgen?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Synairgen already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Synairgen's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It looks like hedge funds own 16% of Synairgen shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Looking at our data, we can see that the largest shareholder is Hargreaves Lansdown Asset Management Limited with 18% of shares outstanding. With 16% and 8.8% of the shares outstanding respectively, Polygon Global Partners LLP and Polar Capital Holdings plc are the second and third largest shareholders.

On looking further, we found that 52% of the shares are owned by the top 5 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Synairgen

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Shareholders would probably be interested to learn that insiders own shares in Synairgen plc. As individuals, the insiders collectively own UK£9.2m worth of the UK£368m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 13% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Synairgen. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Synairgen better, we need to consider many other factors. To that end, you should learn about the 4 warning signs we've spotted with Synairgen (including 2 which don't sit too well with us) .

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.